Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Coherus Biosciences and Klinge Biopharma commercialisation agreement- biosimilar aflibercept

Jan 9, 2023

Coherus Biosciences announced that it has executed a binding term sheet with Klinge Biopharma granting Coherus the exclusive US commercialisation rights to Klinge’s FYB203 (biosimilar aflibercept, targeting Bayer’s Eylea®, developed by Regeneron).  Coherus expects to complete the transaction in Q1 2023, and to file a BLA later in 2023.  Coherus plans to launch the product at biosimilar market formation, currently expected to be in 2025.
Print Page Mail Article